Zydus Lifesciences Limited

ZYDUSLIFE

INE010B01027

Pharmaceuticals

Market Closed - NSE India S.E. Other stock markets 07:05:10 2026-07-16 am EDT			5-day change	1st Jan Change
1,153.90 ^INR	-0.26%		+0.51%	+26.20%

Jul. 10	India's Dr Reddy's posts worst week in 3 years as semaglutide setback stokes growth fears	RE
Jul. 03	Zydus Signs MoU with Apollo Hospitals to Offer Guardant Health?s Shield Multi-Cancer Detection Test in India	CI

Zydus Lifesciences Limited announces Annual dividend, payable on September 10, 2026

Published on 05/19/2026 at 04:22 pm EDT

S&P Capital IQ

Add MarketScreener to your sources

ZYDUS LIFESCIENCES LIMITED

-0.26%

Zydus Lifesciences Limited announced Annual dividend of INR 1.0000 per share payable on September 10, 2026, ex-date on July 24, 2026 and record date on July 24, 2026.

Add MarketScreener to your sources

Latest news about Zydus Lifesciences Limited

Jul. 10	India's Dr Reddy's posts worst week in 3 years as semaglutide setback stokes growth fears	RE
Jul. 03	Zydus Signs MoU with Apollo Hospitals to Offer Guardant Health?s Shield Multi-Cancer Detection Test in India	CI
Jul. 03	Zydus Lifesciences Signs MoU With Apollo Hospitals for Multi-Cancer Detection Test; Shares Up 3%	MT
Jun. 26	Zydus Sunshine announced that it expects to receive $5 million in funding from Zydus Lifesciences Limited	CI
Jun. 26	Zydus Lifesciences to Form 50:50 JV With Sunshine Healthcare in Sri Lanka	MT
Jun. 25	Zydus Lifesciences Limited and Sunshine Healthcare Lanka Limited Enter Joint Venture to Establish Zydus Sunshine Lifesciences Private Limited with Investment Commitment	CI
Jun. 16	Zydus Lifesciences Completes Acquisition of US-Based Assertio Holdings	MT
Jun. 16	Assertio Holdings Completes Merger With Zydus Lifesciences	MT
Jun. 10	Zydus Lifesciences Unit Secures Reduction in GST Tax Demands	MT
Jun. 09	Zydus Lifesciences Limited's Equity Buyback announced on May 19, 2026, has expired.	CI
Jun. 08	Zydus Lifesciences Limited Receives Warning Letter from U.S. Food and Drug Administration	CI
Jun. 03	Zydus Lifesciences Receives USFDA Warning Letter for Baddi Facility	MT
May. 28	Zydus Lifesciences says US FDA grants priority review to Zydus Therapeutics' NDA for saroglitazar to treat pbc	RE
May. 27	Zydus Lifesciences share buyback price increased from 1,150 rupees per share to 1,260 rupees per share	RE
May. 20	Zydus Lifesciences to Seek Acquisitions in Specialty and Rare Disease Segments	CI

Chart Zydus Lifesciences Limited

Duration

Period

ZYDUSLIFE: Dynamic Chart

Zydus Lifesciences Limited is an India-based life-sciences company with positions across pharmaceuticals and consumer wellness, supported by a MedTech franchise and a global footprint across United States, India and other international markets. Its pharmaceutical business includes integrated pharmaceutical operations with business encompassing the entire value chain in research, development, production, marketing and distribution of pharmaceutical products. Its product portfolio includes active pharmaceutical ingredients, human formulations, and animal health and veterinary. Its consumer products business includes development, production, marketing and distribution of differentiated health and wellness products. It provides biologicals manufacturing sites offering contract development and manufacturing organization services to biopharmaceutical companies globally. Its focused therapy areas include cardiology, anti-diabetes, super specialty areas of oncology and nephrology, and others.

Employees

29,980

Sector

Pharmaceuticals

Calendar

Jul. 24 - Ex-dividend date - 1 INR

More about the company